Instalab
logoInstalab

Small LDL-P

See whether a normal cholesterol result is missing a higher-risk particle pattern, especially when blood sugar or triglycerides run high.
4.8 (2,593 reviews)
Tested by Quest or Access Medical
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Small LDL-P test?

This test is most useful if any of these apply to you.

Healthy but Want to Stay Ahead
Your routine labs look fine and you want to know whether a higher-risk particle pattern is forming.
Told Your LDL Is Normal
A normal LDL cholesterol can hide a high count of small particles, especially when triglycerides run high.
Living With Prediabetes or Diabetes
Insulin resistance pushes small particles up, and with diabetes and heart disease this pattern tracks future events.
Carrying Weight Around Your Middle
Waist size tracks small dense particles more closely than BMI, so this shows whether belly fat is shifting your pattern.

About Small LDL-P

Maybe your standard cholesterol panel came back fine, but you carry weight around your middle, your fasting blood sugar is creeping up, or your triglycerides run high. This test asks whether "fine" is the full picture. It counts the smallest, densest cholesterol-carrying particles in the LDL family, the pattern that often builds when triglycerides, blood sugar, and waist size are running high.

In large studies, people with more of these particles, or related small dense LDL measurements, have had more heart disease and more narrowed arteries, sometimes even when LDL cholesterol looked unremarkable. The test is still an emerging one. No major guideline sets a treatment target for it, and the major lipid guidelines do not recommend routine LDL subfraction testing. It works best as a sharper lens on risk, read next to the core markers.

What the Test Counts

LDL stands for low-density lipoprotein. It is the family of particles that carries cholesterol from your liver out to the rest of your body. Each LDL particle carries one copy of apoB. Total LDL particle count counts LDL particles directly, while apoB counts LDL plus other artery-clogging particles such as VLDL, IDL, and Lp(a). Small LDL-P narrows the count to the smallest, densest part of the LDL family.

Your result comes back in nmol/L, a particle count in a fixed amount of blood. That is different from the weight of cholesterol those particles carry. This test uses ion mobility. The lab first separates the lipoproteins from the rest of your blood, then sorts the particles by size and counts each size band directly.

Other labs count small LDL with NMR spectroscopy, which estimates particle size from magnetic signals instead. Some labs measure the cholesterol inside small dense LDL. None of these methods is standardized against the others, and they give different numbers for the same blood. Much of the research below used NMR or a cholesterol-based measure. The direction of risk often carries over to an ion mobility result, but the exact figures do not.

Why Smaller Particles Often Travel With Higher Risk

Small dense LDL starts out as the same liver-made particles as the rest of your LDL. When your liver sends out more triglyceride-rich particles, as it tends to in obesity and diabetes, enzymes in the bloodstream trim them down, and a bigger share of what's left is small and dense.

Mechanistic studies suggest several reasons this pattern tracks with plaque. Smaller particles bind less well to the receptors your liver uses to clear LDL, so they can stay in circulation longer. They can also enter artery walls, stick to wall tissue, and undergo oxidation. Oxidation is a chemical change that makes LDL more inflammatory. These features help explain the risk signal, but they do not make particle size more important than total apoB particle number.

Heart Attack and Coronary Disease

The strongest evidence is for coronary heart disease, where the arteries feeding your heart narrow. In a pooled analysis of prospective studies, people with high small dense LDL measures had about 36% higher risk of coronary heart disease than people with low levels. The Framingham Offspring Study followed about 3,100 adults and measured the cholesterol carried inside small dense LDL, a related but different measurement. It was the lipid measure most strongly tied to future artery disease in that analysis.

Older studies point the same way. In about 2,100 men in Quebec, small dense LDL predicted heart disease from poor blood flow, partly independent of standard lipid levels. A California study linked smaller LDL particles to coronary artery disease in both men and women.

Small LDL also shows up before symptoms do. In about 280 adults at intermediate risk who had no symptoms, NMR-measured small LDL particle number predicted calcium buildup in the coronary arteries, which is a direct sign of plaque. That held after accounting for LDL cholesterol, HDL, triglycerides, and large LDL particles.

Leg Arteries, Neck Arteries, and Stroke

The same particles reach every artery in your body, so researchers have looked beyond the heart as well. Three studies stand out.

Who Was StudiedWhat Was ComparedWhat They Found
About 28,000 initially healthy women, followed for about 15 yearsSmall LDL particle count versus LDL cholesterol as predictors of new narrowing in the leg arteriesSmall particle count predicted new leg artery disease, and LDL cholesterol did not
About 2,200 adults in a multi-ethnic US study, followed for about 9 yearsSmall LDL particles and apoB versus standard cholesterol measures for growth of plaque in the neck arteriesBoth tracked plaque growth and added information beyond traditional risk factors
About 1,160 adults in SpainLDL made up of more medium and small particles versus mostly large onesA shift toward smaller particles went with higher risk of coronary disease and stroke

Sources: Women's Health Study (Aday et al.); Multi-Ethnic Study of Atherosclerosis (Steffen et al.); Hortega Follow-up Study (Pichler et al.).

The Women's Health Study is the clearest of the three for this exact pattern: women in the highest small LDL particle group had a little more than double the risk of leg artery disease compared with those in the lowest group. The neck-artery study points in the same direction, though apoB and total particle burden remained at least as important as the small-particle fraction.

Diabetes, Insulin Resistance, and Pregnancy

Insulin resistance is the state where your body needs more insulin to keep blood sugar in check, and a high small LDL-P is one of its clearest lipid clues. In the Framingham Heart Study, a raised small particle count was a prominent feature of metabolic syndrome. Metabolic syndrome is the cluster of belly fat, high blood pressure, high triglycerides, low HDL, and elevated blood sugar. In about 4,100 Brazilian adults, waist size was more strongly linked to small dense LDL than BMI was, and the link was stronger in people with insulin resistance or diabetes.

Diabetes is where the signal seems to carry the most weight for predicting what happens next. Among about 4,100 people with proven coronary artery disease, those with diabetes and the highest small dense LDL cholesterol, a related measurement, had nearly double the rate of major cardiovascular events compared with the lowest group. In people with normal blood sugar or prediabetes, the same marker did not clearly separate higher from lower risk.

In pregnancy, a small study of 84 women linked a higher ratio of small dense to large LDL particles with gestational diabetes and higher fasting blood sugar.

Particle Count Versus Particle Size

The biggest open question about this test is whether particle size adds anything once you know the total particle count, and several large studies say it mostly does not. In about 207,000 people, total count of apoB-containing particles predicted coronary disease, and particle type and size added little once that count was known. When LDL cholesterol and LDL particle count disagree, risk tends to follow the particle count.

In the Framingham Heart Study, people with metabolic syndrome had more small LDL particles, but within that group the extra small particles were not tied to higher event rates. In a multi-ethnic US group with normal blood sugar, the cholesterol in small dense LDL, apoB, and total LDL particle count predicted coronary disease about equally well. Guidelines reflect this. They anchor treatment on apoB, non-HDL cholesterol, and LDL cholesterol, and the major US and European lipid guidelines do not recommend routine LDL subfraction testing or set any target for it.

These findings fit together once you read small LDL-P as a pattern marker. Each small particle carries less cholesterol, so a person with mostly small particles needs more of them to carry the same cholesterol, and a high small count usually comes with a high total count. Much of the risk travels with that total. What the small count adds is a fingerprint of the metabolic state driving it, and it explains why your LDL cholesterol can understate how many particles you have.

So read your small LDL-P next to apoB or total LDL particle count. The total is the number to bring down. The small count tells you how much of the problem comes from insulin resistance and triglycerides, which shapes how you go after it.

When Results Can Be Misleading

The most common source of confusion with this test is the method used to run it.

  • Method differences: in about 100 treated patients tested by NMR, ion mobility, and a third method, the tests disagreed on risk-category calls roughly 37% of the time. Compare an ion mobility result only with another ion mobility result, ideally from the same lab.
  • Run-to-run variation: ion mobility measures LDL peak size very precisely, but repeat runs of subfraction counts like this one can vary by up to about 20%, so small changes may be noise.
  • Metabolic swings: small LDL rises along with triglycerides, blood sugar, and waist size, so a stretch of weight gain or poorly controlled blood sugar can push it up before you've changed anything else.
  • Age and sex: lipoprotein profiles shift with age in different ways for men and women, with noticeable changes around midlife, so your own trend means more than a comparison with someone else.
  • Lab factors: sample handling or other lab issues can affect a particle result, which is one more reason to confirm a surprising number.

Tracking Your Trend

Within a single method and lab, advanced particle assays are useful for following broad changes, but small subclass counts vary more than headline LDL measures. Treat moves under about 20% cautiously. Your biology also moves the number: triglycerides, weight, blood sugar control, and medications all shift it, which is why one reading is a snapshot and a series of readings is the picture.

Use the same lab and the same method every time, because switching between ion mobility and NMR can create a change that is not real.

Repeat testing is how you see whether a change is moving this specific number. Most trial data on small particle counts comes from NMR measurements, so expect the direction of a change to match on ion mobility even when the size of the drop differs.

What to Do With a High Result

Start by finding out how many artery-clogging particles you have in total. Check apoB and total LDL particle count alongside this result. If both are high too, you have a particle problem that warrants treatment, and the small count tells you insulin resistance is likely part of the cause.

Then look for the metabolic driver. Check fasting insulin, glucose, HbA1c, and triglycerides. HbA1c reflects average blood sugar over about three months. High triglycerides and low HDL alongside a high small count is the classic insulin-resistance pattern, and in that case the fix runs through blood sugar, weight, and triglycerides as much as through cholesterol.

If small LDL-P is high but apoB and total particle count are low, your risk is probably lower than the small count alone would suggest, though the metabolic pattern behind it is still worth addressing. A coronary calcium scan helps in either case, because it shows whether plaque has already formed, and that changes how hard to push.

Bring in a lipidologist or preventive cardiologist if apoB stays high despite changes, if you have diabetes along with known coronary disease, or if you also carry high Lp(a). Lp(a) is a separate, mostly inherited particle that a one-time test can identify.

What Moves This Biomarker

Evidence-backed interventions that affect your Small LDL-P level

↓ Decrease
Take a PCSK9 inhibitor (alirocumab), an injectable drug that helps your liver clear more LDL from the blood, on top of a statin
This cuts your small LDL particle count roughly in half, along with your total and large LDL particles, so the whole particle burden drops. In a randomized trial of people with high cholesterol already on atorvastatin, adding alirocumab lowered small LDL particle count by about 54%. Particle size changed little, which means the drug worked by lowering particle numbers across every size. These counts were measured by NMR spectroscopy, a different method from this test's ion mobility, so the exact drop may differ on your report.
MedicationStrong Evidence
↓ Decrease
Eat a carbohydrate-restricted diet
Cutting carbohydrates lowers your small LDL particle count and shifts your LDL toward larger particles, the pattern linked to lower risk. A meta-analysis of 38 randomized trials found that carbohydrate-restricted diets raised LDL peak particle size and lowered both total and small LDL particle numbers. Part of the effect seems to come from weight loss and the drop in triglycerides that goes with it.
DietModerate Evidence
↓ Decrease
Take an SGLT2 inhibitor (dapagliflozin), a diabetes drug that makes your kidneys flush extra sugar into the urine
In type 2 diabetes, this drug shifts LDL away from small dense particles even when LDL cholesterol does not change. In a randomized trial, dapagliflozin lowered the cholesterol carried in small dense LDL by about 20% and raised large buoyant LDL, while sitagliptin, a comparison diabetes drug, did not. The trial measured cholesterol in small dense LDL, a related measurement, rather than counting particles, so the effect on this test's particle count has not been measured directly.
MedicationModerate Evidence
↑ Increase
Take obeticholic acid, a liver drug used in fatty liver disease trials
This drug raised both large and small dense LDL particles within 12 weeks, which adds to your artery-clogging particle burden. In a randomized trial of people with inflammatory fatty liver disease, the particle changes reversed after the drug was stopped. If you take it, track your particle counts and apoB.
MedicationModerate Evidence
↓ Decrease
Take a statin (pitavastatin or atorvastatin)
Statins usually lower small dense LDL along with total LDL, though the effect on the small fraction varies. In type 2 diabetes, pitavastatin cut the share of LDL that was small and dense from about 30% to about 20% and raised average particle size. After a heart attack, atorvastatin mainly lowered the small LDL subfractions. A small randomized trial of atorvastatin plus ezetimibe, measured by gel electrophoresis, lowered large LDL but not small dense LDL, so retest to see how your own number responds.
MedicationModerate Evidence
↓ Decrease
Take high-dose omega-3 fatty acids (about 4 g per day) alongside a statin
In people with type 2 diabetes on a statin, high-dose omega-3s lower triglycerides and shift LDL toward larger particles. In a randomized trial, adding omega-3s raised LDL particle size and lowered triglycerides. A small pilot study in diabetes with high triglycerides found fewer small LDL particles and a higher ratio of large to small. These studies measured particle size or used other methods, so the effect on an ion mobility small particle count is indirect.
SupplementModest Evidence
↓ Decrease
Take L-carnitine alongside simvastatin
Adding L-carnitine to a statin shrank the share of small LDL particles and raised average LDL size more than the statin did on its own. This comes from a randomized trial in type 2 diabetes. The trial reported the proportion of small particles rather than an ion mobility count, so the effect on your number is indirect.
SupplementModest Evidence
↓ Decrease
Take pemafibrate, a triglyceride-lowering drug in the fibrate family
In type 2 diabetes with high triglycerides, pemafibrate lowered triglycerides and a small dense LDL signal measured by gel electrophoresis. LDL cholesterol can rise at the same time as particles shift toward larger sizes, so a higher LDL cholesterol on this drug does not tell the whole story. Check apoB to see whether the total artery-clogging particle count improved.
MedicationModest Evidence
↓ Decrease
Do a supervised long-term fast (14 days at about 250 calories per day)
Two weeks of very-low-calorie fasting lowered both large and small LDL particle counts and improved the overall artery-damaging particle profile. This comes from a single uncontrolled study, and the method differs from this test, so treat it as a signal and not a plan.
DietModest Evidence

Frequently Asked Questions

References

63 studies
  1. M. P. Caulfield, S. Li, G. Lee, P. J. Blanche, W. a. Salameh, W. H. Benner, R. E. Reitz, R. M. KraussClinical Chemistry2008
  2. Sanghoon Kim, Ji-won Lee, Yaeji Lee, Youhyun Song, J. a. LintonLipids in Health and Disease2023

Small LDL-P Testing Options

$55

See the particle-level heart risk hiding behind a normal cholesterol result.

Includes 6 biomarkers:
Small LDL-PLDL-PMedium LDL-PLarge HDL-PLDL Peak Size
$149

See whether your particle count is driving heart risk even when your cholesterol number looks fine.

13 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant